Transcriptional Profiling and miRNA-Target Network Analysis Identify Potential Biomarkers for Efficacy Evaluation of Fuzheng-Huayu Formula-Treated Hepatitis B Caused Liver Cirrhosis
Fuzheng-Huayu (FZHY) formula has been found to have a satisfactory effect on hepatitis B-caused cirrhosis (HBC) treatment. However, the efficacy evaluation of FZHY is often challenging. In this study, a randomized, double-blind and placebo-controlled trial was used to evaluate the therapeutic effica...
Gespeichert in:
| Veröffentlicht in: | International journal of molecular sciences 2016-06, Vol.17 (6), p.883-883 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 883 |
|---|---|
| container_issue | 6 |
| container_start_page | 883 |
| container_title | International journal of molecular sciences |
| container_volume | 17 |
| creator | Chen, Qilong Wu, Feizhen Wang, Mei Dong, Shu Liu, Yamin Lu, Yiyu Song, Yanan Zhou, Qianmei Liu, Ping Luo, Yunquan Su, Shibing |
| description | Fuzheng-Huayu (FZHY) formula has been found to have a satisfactory effect on hepatitis B-caused cirrhosis (HBC) treatment. However, the efficacy evaluation of FZHY is often challenging. In this study, a randomized, double-blind and placebo-controlled trial was used to evaluate the therapeutic efficacy of FZHY in HBC treatment. In the trial, 35 medical indexes were detected, and 14 indexes had a statistically-significant difference before compared to after the trial. Importantly, the Child-Pugh score also demonstrated FZHY having therapeutic efficacy. Furthermore, the microRNA (miRNA) profiles of 12 serum samples were detected in FZHY groups, and 112 differential-expressed (DE) miRNAs were determined. Using predicted miRNA targets, 13 kernel miRNAs were identified from the established miRNA-target network. Subsequently, quantitative Real-time Polymerase Chain Reaction (qRT-PCR) was used to validate the expression level of 13 identified miRNAs in the trials. The results showed that nine miRNAs have a statistically-significant difference before compared to after FZHY treatment. By means of a logistic regression model, a miRNA panel with hsa-miR-18a-5p, -326, -1182 and -193b-5p was established, and it can clearly improve the accuracy of the efficacy evaluation of FZHY. This study suggested that the particular miRNAs can act as potential biomarkers and obviously increase the diagnostic accuracy for drug evaluation in HBC treatment progression. |
| doi_str_mv | 10.3390/ijms17060883 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4926417</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1795861000</sourcerecordid><originalsourceid>FETCH-LOGICAL-c445t-ee266fe8451eab9ad38d93332499a048c7d1bec1f6b1bbe1c2fc93f4ffcdadcf3</originalsourceid><addsrcrecordid>eNqFkkuP0zAUhSMEYh6wY40ssWFBwK868QapU7V0pGoYobKOHOe6dSeJix0XZf4X_w9XM4wKG1a-sj-f4yOfLHtD8EfGJP5kd10gBRa4LNmz7JxwSnOMRfH8ZD7LLkLYYUwZnciX2RktaEEEYefZr7VXfdDe7gfretWiW--MbW2_QapvUGe_3UzztfIbGNANDD-dv0PTxI3BBnTdQD9YM6JbNxyndP3Kuk75O_ABGefR3BirlR7R_KDaqI4eyBm0iPdb6Df5MqoxooXzXWxVvvagBmjQEvaJHJLBFZqpGNLWyh7Ao5n1fuuS86vshVFtgNeP62X2fTFfz5b56uuX69l0lWvOJ0MOQIUwUPIJAVVL1bCykYwxyqVUmJe6aEgNmhhRk7oGoqnRkhlujG5Uow27zD4_6O5j3UGjU0iv2mrvbQo5Vk7Z6u-T3m6rjTtUXFLBSZEE3j8KePcjQhiqzgYNbat6cDFUpGQFY6Xk5f_RQk5KQTDGCX33D7pz0adfOQpiToXERCTqwwOlvQvBg3l6N8HVsTrVaXUS_vY06xP8pyvsN4W7xPQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1804269016</pqid></control><display><type>article</type><title>Transcriptional Profiling and miRNA-Target Network Analysis Identify Potential Biomarkers for Efficacy Evaluation of Fuzheng-Huayu Formula-Treated Hepatitis B Caused Liver Cirrhosis</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Chen, Qilong ; Wu, Feizhen ; Wang, Mei ; Dong, Shu ; Liu, Yamin ; Lu, Yiyu ; Song, Yanan ; Zhou, Qianmei ; Liu, Ping ; Luo, Yunquan ; Su, Shibing</creator><creatorcontrib>Chen, Qilong ; Wu, Feizhen ; Wang, Mei ; Dong, Shu ; Liu, Yamin ; Lu, Yiyu ; Song, Yanan ; Zhou, Qianmei ; Liu, Ping ; Luo, Yunquan ; Su, Shibing</creatorcontrib><description>Fuzheng-Huayu (FZHY) formula has been found to have a satisfactory effect on hepatitis B-caused cirrhosis (HBC) treatment. However, the efficacy evaluation of FZHY is often challenging. In this study, a randomized, double-blind and placebo-controlled trial was used to evaluate the therapeutic efficacy of FZHY in HBC treatment. In the trial, 35 medical indexes were detected, and 14 indexes had a statistically-significant difference before compared to after the trial. Importantly, the Child-Pugh score also demonstrated FZHY having therapeutic efficacy. Furthermore, the microRNA (miRNA) profiles of 12 serum samples were detected in FZHY groups, and 112 differential-expressed (DE) miRNAs were determined. Using predicted miRNA targets, 13 kernel miRNAs were identified from the established miRNA-target network. Subsequently, quantitative Real-time Polymerase Chain Reaction (qRT-PCR) was used to validate the expression level of 13 identified miRNAs in the trials. The results showed that nine miRNAs have a statistically-significant difference before compared to after FZHY treatment. By means of a logistic regression model, a miRNA panel with hsa-miR-18a-5p, -326, -1182 and -193b-5p was established, and it can clearly improve the accuracy of the efficacy evaluation of FZHY. This study suggested that the particular miRNAs can act as potential biomarkers and obviously increase the diagnostic accuracy for drug evaluation in HBC treatment progression.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms17060883</identifier><identifier>PMID: 27271613</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Biomarkers ; Cluster Analysis ; Computational Biology - methods ; Drugs, Chinese Herbal - pharmacology ; Drugs, Chinese Herbal - therapeutic use ; Gene Expression Profiling ; Gene Expression Regulation ; Gene Regulatory Networks ; Hepatitis ; Hepatitis B - complications ; Hepatitis B virus ; Humans ; Liver cirrhosis ; Liver Cirrhosis - drug therapy ; Liver Cirrhosis - etiology ; Liver Cirrhosis - pathology ; MicroRNAs ; MicroRNAs - genetics ; Protein expression ; RNA Interference ; ROC Curve ; Transcriptome ; Treatment Outcome</subject><ispartof>International journal of molecular sciences, 2016-06, Vol.17 (6), p.883-883</ispartof><rights>Copyright MDPI AG 2016</rights><rights>2016 by the authors; licensee MDPI, Basel, Switzerland. 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c445t-ee266fe8451eab9ad38d93332499a048c7d1bec1f6b1bbe1c2fc93f4ffcdadcf3</citedby><cites>FETCH-LOGICAL-c445t-ee266fe8451eab9ad38d93332499a048c7d1bec1f6b1bbe1c2fc93f4ffcdadcf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926417/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926417/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27271613$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Qilong</creatorcontrib><creatorcontrib>Wu, Feizhen</creatorcontrib><creatorcontrib>Wang, Mei</creatorcontrib><creatorcontrib>Dong, Shu</creatorcontrib><creatorcontrib>Liu, Yamin</creatorcontrib><creatorcontrib>Lu, Yiyu</creatorcontrib><creatorcontrib>Song, Yanan</creatorcontrib><creatorcontrib>Zhou, Qianmei</creatorcontrib><creatorcontrib>Liu, Ping</creatorcontrib><creatorcontrib>Luo, Yunquan</creatorcontrib><creatorcontrib>Su, Shibing</creatorcontrib><title>Transcriptional Profiling and miRNA-Target Network Analysis Identify Potential Biomarkers for Efficacy Evaluation of Fuzheng-Huayu Formula-Treated Hepatitis B Caused Liver Cirrhosis</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>Fuzheng-Huayu (FZHY) formula has been found to have a satisfactory effect on hepatitis B-caused cirrhosis (HBC) treatment. However, the efficacy evaluation of FZHY is often challenging. In this study, a randomized, double-blind and placebo-controlled trial was used to evaluate the therapeutic efficacy of FZHY in HBC treatment. In the trial, 35 medical indexes were detected, and 14 indexes had a statistically-significant difference before compared to after the trial. Importantly, the Child-Pugh score also demonstrated FZHY having therapeutic efficacy. Furthermore, the microRNA (miRNA) profiles of 12 serum samples were detected in FZHY groups, and 112 differential-expressed (DE) miRNAs were determined. Using predicted miRNA targets, 13 kernel miRNAs were identified from the established miRNA-target network. Subsequently, quantitative Real-time Polymerase Chain Reaction (qRT-PCR) was used to validate the expression level of 13 identified miRNAs in the trials. The results showed that nine miRNAs have a statistically-significant difference before compared to after FZHY treatment. By means of a logistic regression model, a miRNA panel with hsa-miR-18a-5p, -326, -1182 and -193b-5p was established, and it can clearly improve the accuracy of the efficacy evaluation of FZHY. This study suggested that the particular miRNAs can act as potential biomarkers and obviously increase the diagnostic accuracy for drug evaluation in HBC treatment progression.</description><subject>Biomarkers</subject><subject>Cluster Analysis</subject><subject>Computational Biology - methods</subject><subject>Drugs, Chinese Herbal - pharmacology</subject><subject>Drugs, Chinese Herbal - therapeutic use</subject><subject>Gene Expression Profiling</subject><subject>Gene Expression Regulation</subject><subject>Gene Regulatory Networks</subject><subject>Hepatitis</subject><subject>Hepatitis B - complications</subject><subject>Hepatitis B virus</subject><subject>Humans</subject><subject>Liver cirrhosis</subject><subject>Liver Cirrhosis - drug therapy</subject><subject>Liver Cirrhosis - etiology</subject><subject>Liver Cirrhosis - pathology</subject><subject>MicroRNAs</subject><subject>MicroRNAs - genetics</subject><subject>Protein expression</subject><subject>RNA Interference</subject><subject>ROC Curve</subject><subject>Transcriptome</subject><subject>Treatment Outcome</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkkuP0zAUhSMEYh6wY40ssWFBwK868QapU7V0pGoYobKOHOe6dSeJix0XZf4X_w9XM4wKG1a-sj-f4yOfLHtD8EfGJP5kd10gBRa4LNmz7JxwSnOMRfH8ZD7LLkLYYUwZnciX2RktaEEEYefZr7VXfdDe7gfretWiW--MbW2_QapvUGe_3UzztfIbGNANDD-dv0PTxI3BBnTdQD9YM6JbNxyndP3Kuk75O_ABGefR3BirlR7R_KDaqI4eyBm0iPdb6Df5MqoxooXzXWxVvvagBmjQEvaJHJLBFZqpGNLWyh7Ao5n1fuuS86vshVFtgNeP62X2fTFfz5b56uuX69l0lWvOJ0MOQIUwUPIJAVVL1bCykYwxyqVUmJe6aEgNmhhRk7oGoqnRkhlujG5Uow27zD4_6O5j3UGjU0iv2mrvbQo5Vk7Z6u-T3m6rjTtUXFLBSZEE3j8KePcjQhiqzgYNbat6cDFUpGQFY6Xk5f_RQk5KQTDGCX33D7pz0adfOQpiToXERCTqwwOlvQvBg3l6N8HVsTrVaXUS_vY06xP8pyvsN4W7xPQ</recordid><startdate>20160603</startdate><enddate>20160603</enddate><creator>Chen, Qilong</creator><creator>Wu, Feizhen</creator><creator>Wang, Mei</creator><creator>Dong, Shu</creator><creator>Liu, Yamin</creator><creator>Lu, Yiyu</creator><creator>Song, Yanan</creator><creator>Zhou, Qianmei</creator><creator>Liu, Ping</creator><creator>Luo, Yunquan</creator><creator>Su, Shibing</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>20160603</creationdate><title>Transcriptional Profiling and miRNA-Target Network Analysis Identify Potential Biomarkers for Efficacy Evaluation of Fuzheng-Huayu Formula-Treated Hepatitis B Caused Liver Cirrhosis</title><author>Chen, Qilong ; Wu, Feizhen ; Wang, Mei ; Dong, Shu ; Liu, Yamin ; Lu, Yiyu ; Song, Yanan ; Zhou, Qianmei ; Liu, Ping ; Luo, Yunquan ; Su, Shibing</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c445t-ee266fe8451eab9ad38d93332499a048c7d1bec1f6b1bbe1c2fc93f4ffcdadcf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Biomarkers</topic><topic>Cluster Analysis</topic><topic>Computational Biology - methods</topic><topic>Drugs, Chinese Herbal - pharmacology</topic><topic>Drugs, Chinese Herbal - therapeutic use</topic><topic>Gene Expression Profiling</topic><topic>Gene Expression Regulation</topic><topic>Gene Regulatory Networks</topic><topic>Hepatitis</topic><topic>Hepatitis B - complications</topic><topic>Hepatitis B virus</topic><topic>Humans</topic><topic>Liver cirrhosis</topic><topic>Liver Cirrhosis - drug therapy</topic><topic>Liver Cirrhosis - etiology</topic><topic>Liver Cirrhosis - pathology</topic><topic>MicroRNAs</topic><topic>MicroRNAs - genetics</topic><topic>Protein expression</topic><topic>RNA Interference</topic><topic>ROC Curve</topic><topic>Transcriptome</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Qilong</creatorcontrib><creatorcontrib>Wu, Feizhen</creatorcontrib><creatorcontrib>Wang, Mei</creatorcontrib><creatorcontrib>Dong, Shu</creatorcontrib><creatorcontrib>Liu, Yamin</creatorcontrib><creatorcontrib>Lu, Yiyu</creatorcontrib><creatorcontrib>Song, Yanan</creatorcontrib><creatorcontrib>Zhou, Qianmei</creatorcontrib><creatorcontrib>Liu, Ping</creatorcontrib><creatorcontrib>Luo, Yunquan</creatorcontrib><creatorcontrib>Su, Shibing</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Qilong</au><au>Wu, Feizhen</au><au>Wang, Mei</au><au>Dong, Shu</au><au>Liu, Yamin</au><au>Lu, Yiyu</au><au>Song, Yanan</au><au>Zhou, Qianmei</au><au>Liu, Ping</au><au>Luo, Yunquan</au><au>Su, Shibing</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Transcriptional Profiling and miRNA-Target Network Analysis Identify Potential Biomarkers for Efficacy Evaluation of Fuzheng-Huayu Formula-Treated Hepatitis B Caused Liver Cirrhosis</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2016-06-03</date><risdate>2016</risdate><volume>17</volume><issue>6</issue><spage>883</spage><epage>883</epage><pages>883-883</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>Fuzheng-Huayu (FZHY) formula has been found to have a satisfactory effect on hepatitis B-caused cirrhosis (HBC) treatment. However, the efficacy evaluation of FZHY is often challenging. In this study, a randomized, double-blind and placebo-controlled trial was used to evaluate the therapeutic efficacy of FZHY in HBC treatment. In the trial, 35 medical indexes were detected, and 14 indexes had a statistically-significant difference before compared to after the trial. Importantly, the Child-Pugh score also demonstrated FZHY having therapeutic efficacy. Furthermore, the microRNA (miRNA) profiles of 12 serum samples were detected in FZHY groups, and 112 differential-expressed (DE) miRNAs were determined. Using predicted miRNA targets, 13 kernel miRNAs were identified from the established miRNA-target network. Subsequently, quantitative Real-time Polymerase Chain Reaction (qRT-PCR) was used to validate the expression level of 13 identified miRNAs in the trials. The results showed that nine miRNAs have a statistically-significant difference before compared to after FZHY treatment. By means of a logistic regression model, a miRNA panel with hsa-miR-18a-5p, -326, -1182 and -193b-5p was established, and it can clearly improve the accuracy of the efficacy evaluation of FZHY. This study suggested that the particular miRNAs can act as potential biomarkers and obviously increase the diagnostic accuracy for drug evaluation in HBC treatment progression.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>27271613</pmid><doi>10.3390/ijms17060883</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1422-0067 |
| ispartof | International journal of molecular sciences, 2016-06, Vol.17 (6), p.883-883 |
| issn | 1422-0067 1661-6596 1422-0067 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4926417 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Biomarkers Cluster Analysis Computational Biology - methods Drugs, Chinese Herbal - pharmacology Drugs, Chinese Herbal - therapeutic use Gene Expression Profiling Gene Expression Regulation Gene Regulatory Networks Hepatitis Hepatitis B - complications Hepatitis B virus Humans Liver cirrhosis Liver Cirrhosis - drug therapy Liver Cirrhosis - etiology Liver Cirrhosis - pathology MicroRNAs MicroRNAs - genetics Protein expression RNA Interference ROC Curve Transcriptome Treatment Outcome |
| title | Transcriptional Profiling and miRNA-Target Network Analysis Identify Potential Biomarkers for Efficacy Evaluation of Fuzheng-Huayu Formula-Treated Hepatitis B Caused Liver Cirrhosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T06%3A56%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Transcriptional%20Profiling%20and%20miRNA-Target%20Network%20Analysis%20Identify%20Potential%20Biomarkers%20for%20Efficacy%20Evaluation%20of%20Fuzheng-Huayu%20Formula-Treated%20Hepatitis%20B%20Caused%20Liver%20Cirrhosis&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Chen,%20Qilong&rft.date=2016-06-03&rft.volume=17&rft.issue=6&rft.spage=883&rft.epage=883&rft.pages=883-883&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms17060883&rft_dat=%3Cproquest_pubme%3E1795861000%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1804269016&rft_id=info:pmid/27271613&rfr_iscdi=true |